Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $42.60 Average Target Price from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given a consensus recommendation of “Moderate Buy” by the five research firms that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $42.60.

COLL has been the subject of a number of recent research reports. HC Wainwright boosted their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Piper Sandler reissued a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors have recently made changes to their positions in the business. nVerses Capital LLC raised its stake in Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 792 shares in the last quarter. CWM LLC raised its position in shares of Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 736 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares in the last quarter. Finally, Virtus Fund Advisers LLC purchased a new stake in Collegium Pharmaceutical during the 3rd quarter worth approximately $72,000.

Collegium Pharmaceutical Trading Down 0.3 %

NASDAQ COLL opened at $29.06 on Thursday. Collegium Pharmaceutical has a one year low of $28.75 and a one year high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market capitalization of $937.19 million, a price-to-earnings ratio of 12.53 and a beta of 0.80. The company’s 50-day simple moving average is $32.12 and its two-hundred day simple moving average is $34.27.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.